MorphoSys (NASDAQ:MOR – Get Rating) had its price objective lowered by analysts at Citigroup from €16.00 ($17.02) to €12.00 ($12.77) in a report issued on Thursday, The Fly reports. The brokerage currently has a “sell” rating on the stock.
MOR has been the subject of a number of other research reports. JMP Securities cut their price objective on shares of MorphoSys from $32.00 to $15.00 and set a “market outperform” rating for the company in a research report on Friday, November 18th. Stifel Nicolaus downgraded shares of MorphoSys from a “buy” rating to a “hold” rating in a research report on Tuesday, November 15th. Deutsche Bank Aktiengesellschaft downgraded shares of MorphoSys from a “hold” rating to a “sell” rating in a research report on Monday, October 24th. Finally, The Goldman Sachs Group downgraded shares of MorphoSys from a “neutral” rating to a “sell” rating in a research report on Friday, December 16th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $21.25.
MorphoSys Price Performance
Shares of MOR opened at $3.37 on Thursday. The firm has a market cap of $461.45 million, a PE ratio of -0.48 and a beta of 0.94. The company has a current ratio of 2.98, a quick ratio of 2.91 and a debt-to-equity ratio of 2.01. The firm has a fifty day simple moving average of $4.51 and a two-hundred day simple moving average of $4.90. MorphoSys has a 1-year low of $3.26 and a 1-year high of $9.86.
MorphoSys (NASDAQ:MOR – Get Rating) last announced its earnings results on Wednesday, November 16th. The company reported ($0.91) earnings per share for the quarter. MorphoSys had a negative net margin of 357.89% and a negative return on equity of 688.39%. The company had revenue of $96.56 million for the quarter. During the same period in the previous year, the company posted ($0.97) EPS. On average, equities analysts anticipate that MorphoSys will post -2.94 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of MOR. UBS Group AG boosted its holdings in shares of MorphoSys by 122.7% during the 3rd quarter. UBS Group AG now owns 5,141 shares of the company’s stock valued at $26,000 after purchasing an additional 2,832 shares during the last quarter. Virtu Financial LLC bought a new position in shares of MorphoSys during the 2nd quarter valued at about $53,000. Citadel Advisors LLC bought a new position in shares of MorphoSys during the 3rd quarter valued at about $101,000. OLD Mission Capital LLC bought a new position in shares of MorphoSys during the 2nd quarter valued at about $195,000. Finally, Optiver Holding B.V. bought a new position in shares of MorphoSys during the 2nd quarter valued at about $340,000. Institutional investors own 2.05% of the company’s stock.
About MorphoSys
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.